

Registered Office: A-109 Express Apartments, Lakdi ka Pool, Hyderabad - 500004

**Corporate Office**: 5<sup>th</sup> floor, Prestige Phoenix, 1405, Uma Nagar, Begumpet, Hyderabad - 500016 +91 8688825013 • info@bankabio.com • www.bankabio.com • CIN: L90001TG2012PLC082811

An ISO 9001-2015-14001-2015-45001-2018 Company

BBL/SECT/33/2024-25

Date: 13 August 2024

To,
The Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051

NSE Symbol: BANKA

Sub: Outcome of Board Meeting dated 13 August 2024.

Ref: Regulation 30 & 33 read with sub-para 4 of Para "A" of Part "A" of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

This is to inform you that the Board of Directors at its Meeting held today, i.e., 13 August 2024, has inter alia, based on the recommendation of the Audit Committee, considered and approved the un-Audited standalone and consolidated financial results of the Company for the quarter ended 30 June 2024.

A copy of the aforementioned Financial Results along with the Auditors' Limited Review Report thereon pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") is enclosed herewith.

We are also arranging to upload the aforesaid Financial Results on the Company's Website at <a href="https://www.bankabio.com">www.bankabio.com</a> and shall publish the Financial Results in the newspapers, in the format prescribed under Regulation 47 of the SEBI Listing Regulations.

The meeting commenced at 03:15 PM and concluded at 04:15 PM.

We request you to kindly take note of the same in your record.

Thank you,

For Banka BioLoo Limited

Nitika Lakhotia Company Secretary & Compliance Officer

Encl: As above

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

### To The Board of Directors of BANKA BIOLOO LIMITED

We have reviewed the accompanying Statement of unaudited standalone financial results of **BANKA BIOLOO LIMITED** for the quarter ended June 30, 2024 (the "statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').

- 1. This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 2. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations including the manner in which it is to be disclosed, or that it contain any material misstatement.



4. The financial results shown under columns "Quarter ended 31.03.2024 -Audited", "Quarter ended 30.06.2023 -Unaudited" and "Year ended 31.03.2024 -Audited" contained in the statement have been reviewed/audited by PRSV and Co LLP, the predecessor auditor, on which they have issued an unmodified conclusion/opinion.

For M/s. B.D. Saboo and Associates

Hyderabad

Chartered Accountants

Firm Registration No: 003505

CA Shyam Sundar Modaried Acco

Partner

Membership No: 213530

Place: Hyderabad Date: 13-08-2024

UDIN: 24213530BKAJYL5298

## BANKA BIOLOO LIMITED

# Unaudited STANDALONE Statement of Financial Results for the Quarter ended 30.06.2024

S. No	Particulars	Quarter Ended			Year Ended
		Unaudited	Audited	Unaudited	Audited
110		30.06.2024	31.03.2024	30.06.2023	31.03.2024
1	Income				
	Revenue from Operations	1238.75	1656.34	810.83	4997.45
	Other income	18.84	19.13	21.17	76.65
	Total Income	1257.59	1675.46	832.00	5074.11
2	Expenses				
	Cost of materials consumed	218.36	345.69	292.66	1175.13
	Changes in inventories of finished goods & work- in-				
	progress	69.68	388.58	43.79	546.85
	Employee benefits expense	701.65	628.18	514.42	2358.10
	Finance costs	67.87	56.83	40.98	200.58
	Depreciation and amortisation expense	45.11	45.40	41.86	172.36
	Other expenses	104.09	195.28	83.80	579.68
	Total expenses	1206.75	1659.96	1017.50	5032.69
3	Profit/(loss) before tax	50.84	15.50	(185.50)	41.42
4	Tax expense				
	(1) Current tax	7.04	(2.75)	-	-
	(2) Taxes for earlier years	-	1.93	-	1.93
	(3) MAT Credit	-	-	-	-
	(4) Deferred tax	1.51	14.04	(1.75)	6.84
	Total Tax expense	8.55	13.21	(1.75)	8.77
5	Profit after tax	42.29	2.29	(183.75)	32.65
	Other comprehensive income				
	Items that will not be reclassified to profit and loss				
	Remeasurement of post-employment benefit				
	obligations	0.00	20.85	0.00	20.85
	Income tax effect on items that will not be reclassified	-	(5.25)	-	(5.25)
	Other comprehensive income for the year	0.00	15.60	0.00	15.60
	Takal assessabasesississassa fandla saas	42.20	17.00	(102.75)	49.25
	Total comprehensive income for the year	42.29	17.89	(183.75)	48.25
6	Paid up equity share capital (Face value Rs. 10/- each)	1084.66	1084.66	1084.66	1084.66
	and up equity share capital (Face value Rs. 107 - each)	1004.00	1004.00	1004.00	1004.00
7	Earnings per share				
_ ′	Basic Earnings per share (in Rs.)	0.39	0.02	(1.69)	0.30
	Diluted Earnings per share (in Rs.)	0.39	0.02	(1.69)	0.30
	Datace Darinings per snare (iii No.)	0.56	0.02	(Not	0.30
		(Not annualised)	(Not annualised)	annualised)	(Annualised)
		FOR & ON BE			

FOR & ON BEHALF OF BOARD OF DIRECTORS

Vishal Murarka

CEO & Executive Director

DIN: 06729485

Place: Hyderabad Date: 13.08.2024

### Notes:

- 1. The above unaudited Standalone Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 13 August 2024.
- The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards ("INDAS") prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under and other accounting principles generally accepted in India and the guidelines issued by SEBI.
- 3. The above Standalone Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
- 4. The Standalone Financial Results for the quarter ended 30 June 2024 have been prepared following the same accounting policies as those followed for the annual financial statements for the year ended 31 March 2024.
- 5. Based on the internal reporting provided to the Chief Operating Decision Maker, the standalone financial results relate to the business of waste water & fecal treatment manufacture, supply and installation of and related AMOC services as the only reportable primary segment of the Company as per the Ind AS 108 "Operating Segments".
- 6. The Company has considered internal and external information up to the date of approval of these standalone financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.
- 7. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For Banka Bioloo Limited

Vishal Murarka

CEO & Executive Director

DIN: 06729485

Place: Hyderabad Date: 13 August 2024 Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
Board of Directors of BANKA BIOLOO LIMITED

- We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of BANKA BIOLOO LIMITED (The Parent") and its subsidiary (The parent and its subsidiaries and its associate together referred to as the "Group") for the quarter ended 30 June 2024 ("the statement"), being submitted by the Parent Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
- 2. This Statement, which is the responsibility of the parent's management and approved by the parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is Limited primarily to inquiries of the Company personnel and analytical procedures applied to financial data and thus provides less assurance that an audit. We have not performed an audit and, accordingly we do not express an audit opinion.


We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended to the extent applicable.

4. The Statement includes the results of the following entities.

Holding/Parent Company
BANKA BIOLOO LIMITED

Wholly Owned Subsidiary
ENZOTECH SOLUTIONS PRIVATE LIMITED

<u>Subsidiary</u> MEGALITER VARUNAA PRIVATE LIMITED



#### Associate

SAI BANKA SPV PRIVATE LIMITED (with a share of 50% to the holding company)

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Accounting Standards prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatements.

#### Other Matter

We did not review the interim financial information of 2 subsidiary included in the unaudited consolidated financial results, which have not been reviewed by their auditor, whose interim financial information reflect total revenues of Rs. 56.10 Lacs, total net loss after tax of Rs. (14.79) Lacs and total comprehensive loss of Rs. (14.79) Lacs for the quarter ended June 30, 2024, as considered in the statement. The statement also includes financial results of 1 associate as mentioned above, whose share of net profit after tax of Rs. 0.73 Lacs and total comprehensive income of Rs. 0.73 Lacs for the quarter ended June 30, 2024, as considered in the unaudited consolidated financial results, based on their interim financial results which have not been reviewed and which has been furnished to us by the Management. According to the information and explanations given to us by the management, these unaudited interim standalone financial results are not material to the group.

5. The financial results shown under columns "Quarter ended 31.03.2024 -Audited", "Quarter ended 30.06.2023 -Unaudited" and "Year ended 31.03.2024 -Audited" contained in the statement have been reviewed/audited by PRSV and Co LLP, the predecessor auditor, on which they have issued an unmodified conclusion/opinion.

Hyderabad

For B.D. Saboo and Associates

Chartered Accountants Firm Registration No. 0

CA Shyam Sundar Mo

Partner

Membership No. 213530

Place: Hyderabad Date: 13-08-2024

UDIN: 24213530BKAJYK4822

# BANKA BIOLOO LIMITED

# Unaudited CONSOLIDATED Statement of Financial Results for the Quarter ended 30.06.2024

Rs. In lacs

	Particulars	Quarter Ended			Year Ended
S. No		Unaudited Audited Unaudite			Audited
		30.06.2024	31.03.2024	30.06.2023	31.03.2024
1	Income				
	Revenue from Operations	1288.55	1631.31	827.55	4999.62
	Other income	11.33	11.99	17.29	49.45
	Total Income	1299.88	1643.30	844.84	5049.06
2	Expenses				
_	Cost of materials consumed	237.68	343.97	293.07	1,077.49
	Changes in inventories of finished goods & work- in-			_,,,,,	-,
	progress	69.68	376.69	57.76	546.42
	Employee benefits expense	701.65	629.98	529.68	2393.12
	Finance costs	87.46	63.44	50.80	247.45
	Depreciation and amortisation expense	61.84	61.41	45.94	218.87
	Other expenses	104.74	173.63	98.74	619.95
	Total expenses	1263.05	1649.12	1075.98	5103.29
3	Share of profit/(loss) of Associates	0.73	(3.57)	0.84	(2.10)
4	Profit/(loss) before tax	37.57	(9.39)	(230.31)	(56.33)
_					
5	Tax expense	<b>7</b> 04	(0.75)	4.00	
	(1) Current tax	7.04	(2.75)	4.88	-
	(2) Taxes for earlier years	-	1.93	-	1.93
	(3) MAT Credit (4) Deferred tax	- 1 21	-	- (4.70)	- 0.05
	Total Tax expense	1.31 <b>8.36</b>	16.11 <b>15.29</b>	(1.78) <b>3.10</b>	8.85 <b>10.78</b>
	Total Tax expense	8.30	13,29	3.10	10.78
6	Profit after tax	29.21	(24.68)	(233.40)	(67.11)
	Other comprehensive income				
	Items that will not be reclassified to profit and loss				
	Remeasurement of post-employment benefit				
	obligations	-	20.85	-	20.85
	Income tax effect on items that will not be reclassified	-	(5.25)	-	(5.25)
	Other comprehensive income for the year	-	15.60	-	15.60
	Total comprehensive income for the year	29.21	(9.07)	(233.40)	(51.50)
			, ,	,	, ,
	Attributable to		<i>′</i> 0.4≕	(000 1-1	//0.50
	Shareholders of the Company	29.31	(8.17)	(233.40)	(49.64)
	Non controlling interest	(0.09)	(0.90)	-	(1.86)
7	Paid up equity share capital (Face value Rs. 10/- each)	1084.66	1084.66	1084.66	1084.66
8	Earnings per share				
~	Basic Earnings per share (in Rs.)	0.27	(0.22)	(2.15)	(0.60)
	Diluted Earnings per share (in Rs.)	0.27	(0.22)	(2.15)	(0.59)
		(Not	(Not	(Not	` '
		annualised)	annualised)	annualised)	(Annualised)

FOR & ON BEHALF OF BOARD OF DIRECTORS

Vishal Murarka CEO & Executive Director DIN: 06729485

**Date: 13.08.2024** DIN: 0672

Place: Hyderabad

### Notes:

- 1. The above statement of unaudited Consolidated Financial Results was reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 13 August 2024.
- 2. The Consolidated Financial Results have been prepared in accordance with Indian Accounting Standards ("INDAS") prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under and other accounting principles generally accepted in India and the guidelines issued by SEBI.
- 3. The consolidated financial results of the Group include the results of the Company and results of the following entities.

Name of the entity	Status
Enzotech Solutions Pvt Ltd	Wholly owned subsidiary
Megaliter Varunaa Pvt Ltd	Subsidiary
Sai Banka SPV Pvt Ltd	Associate with 50% share to the Company

- 4. The above Consolidated Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
- 5. The Standalone Financial Results for the quarter ended 30 June 2024 have been prepared following the same accounting policies as these followed for the annual financial statements for the year ended 31 March 2024.
- 6. The Company has considered internal and external information up to the date of approval of these Consolidated financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.
- 7. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For Banka Bioloo Limited

Vishal Murarka

Place: Hyderabad CEO & Executive Director

Date: 13 August 2024 DIN: 06729485